AbbVie: Expect Smaller Deals Near-Term After 2023’s Big Finish
Executive Summary
At the J.P. Morgan conference, AbbVie president Robert Michael said the company must effectively integrate ImmunoGen and Cerevel, which it expects to drive long-term growth.